# NCT04592913 (NCT04592913)

> Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04592913
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Gastrointestinal Neoplasms; Esophagogastric Junction
- Interventions: Durvalumab; FLOT chemotherapy
- Enrollment: 957
- Primary outcome: Event-free survival (EFS)

## Commentary we found

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04592913